Question 1

What are the most cited papers from CritiTech (United States)?

Accepted Answer

The most cited paper from CritiTech (United States) is "A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies" (Stephen K. Williamson, Gary Alan Johnson, Holly A. Maulhardt et al., 2015), with 69 citations. Next come "Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac ® ) in a Rodent Model" (24) and "Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies" (20).

Question 2

Which research topics does CritiTech (United States) publish most on?

Accepted Answer

By volume in 2022-now: Immunotherapy and Immune Responses, Inhalation and Respiratory Drug Delivery, Nanoparticle-Based Drug Delivery and Immune cells in cancer.

Question 3

Which fields of science does CritiTech (United States) work in?

Accepted Answer

In all years, 53% of research at CritiTech (United States) is in Health Sciences, 36% in Life Sciences. Its largest fields are Medicine (47%), Biochemistry, Genetics and Molecular Biology (21%), Immunology and Microbiology (9%). It does 1.3× the world's share of Health Sciences.

Question 4

Is CritiTech (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 26% higher than in 2018-2021.